#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Dent's disease Drug eruption Tourette's disorder Nephrotic syndrome Short-bowel syndrome Blastic plasmacytoid dendritic cell neoplasia Adenocarcinoma gastric Infection in an immunocompromised host Hypochromic anaemia Hidradenitis Acquired C1 inhibitor deficiency Acute lymphocytic leukaemia Juvenile idiopathic arthritis Hodgkin's disease Polycystic liver disease More trials…

    Learn about Rare Diseases

    Adrenogenital syndrome – Trials in Disease Propionic acidaemia – Basic Information Chondrosarcoma metastatic Angiosarcoma – Basic Information Encephalitis autoimmune – Life with Disease Carcinoid syndrome – Basic Information Ewing’s sarcoma metastatic – Diagnostics KBG syndrome – Diagnostics Marginal zone lymphoma Chondrosarcoma metastatic – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    L-ARGININE Panobinostat Tigecycline Fludeoxyglucose (18F) Chloropyramine Hydrochloride Piracetam Cholic Acid Ulipristal Acetate Orlistat [18F]-Altanserin Ep262 Carbamazepine Betamethasone Valerate Allo-647 Domvanalimab Lolium Perenne ALE.P02 Diacerein Nvl-655 Sodium Sulfate Anhydrous More therapies…

    Learn about Your Condition

    Colon cancer stage IV Synovial sarcoma metastatic Proteus syndrome Neoplasm malignant Dyskinesia Neurodermatitis Primary myelofibrosis Huntington's disease Schizophrenia Non-obstructive cardiomyopathy Compulsive sexual behaviour Sepsis Thermal burn Alport's syndrome Diverticulitis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Myotonic dystrophy

  • Study on the Effects of Metformin for Improving Muscle Function in Patients with Myotonic Dystrophy Type 1

    Recruiting

    3 1 1
    Investigated Drugs:
    • Metformin Hydrochloride
    France

  • Study on ATX-01 for Adults Aged 18-64 with Myotonic Dystrophy Type 1 (DM1)

    Recruiting

    1 1
    Investigated Drugs:
    • 16-Base Single Stranded Rna Targeting Mir-23B Linked To Oleic Acid
    France Italy The Netherlands Spain

  • Study on the Safety of VX-670 for Adults with Myotonic Dystrophy Type 1

    Recruiting

    2 1
    Investigated Drugs:
    • Vx-670
    Belgium France Germany Italy The Netherlands Spain

  • A study testing the safety and effects of ADS-019 in adults aged 18 to 65 years with type 1 myotonic dystrophy

    Not yet recruiting

    2 1
    Investigated Diseases:
    • Myotonic dystrophy
    Investigated Drugs:
    • ADS-019
    Belgium Germany Italy Spain

  • Study on AOC 1001 for Treating Myotonic Dystrophy Type 1 in Patients

    Not recruiting

    3 1
    Investigated Drugs:
    • Humanised Igg1 Monoclonal Antibody Against Tfr1 Conjugated To Double Stranded Sirna Oligonucleotide Against Dmpk Via A Non-Cleavable Linker
    Denmark France Germany Ireland Italy The Netherlands +1

  • Safety and effectiveness study of DYNE-101 in patients with Myotonic Dystrophy Type 1 (DM1)

    Not recruiting

    2 1
    Investigated Diseases:
    • Myotonic dystrophy
    Investigated Drugs:
    • Humanised Igg1 Kappa Fragment Antibody Targeting Tfr1 Conjugated To P125 Oligonucleotide
    France Germany Italy The Netherlands
Previous Page
1 2

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!